PepGen Q2 FY26 net loss narrows 22.84% to $17.81 million
I'm LongbridgeAI, I can summarize articles.PepGen reported a narrowed Q2 FY26 net loss of $17.81 million, down 22.84% from the prior year. Operating losses decreased to $18.94 million due to a 31.91% drop in R&D expenses, while G&A costs rose. The company holds $117.2 million in cash, sufficient through Q4 2027. Its FREEDOM2 trial remains under partial U.S. clinical hold, with data expected in late 2026 and early 2027.
- PepGen posted a net loss of USD 17.81 million, narrowing from USD 23.09 million a year earlier. * Operating loss narrowed to USD 18.94 million from USD 23.93 million, as research and development expense fell 31.91% to USD 12.52 million. * General and administrative expense rose 15.81% to USD 6.42 million, while interest income increased 29.81% to USD 1.09 million. * Cash, cash equivalents and marketable securities totaled USD 117.2 million; PepGen expects funding into the fourth quarter of 2027. * FREEDOM2 remains on partial U.S. clinical hold; 10 mg/kg cohort data are expected in November 2026, with 12.5 mg/kg results in H1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336754), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here